Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial

BACKGROUND: In the phase 2/3 BLAZE-1 trial, bamlanivimab and etesevimab together reduced coronavirus disease 2019 (COVID-19)–related hospitalizations and any-cause mortality in ambulatory patients. Herein, we assess the impact of bamlanivimab and etesevimab treatment on the severity and length of sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Peter, Behre, Gerhard, Hebert, Corey, Kumar, Princy, Farmer Macpherson, Lisa, Graham-Clarke, Peita Louise, De La Torre, Inmaculada, Nichols, Russell M, Hufford, Matthew M, Patel, Dipak R, Naegeli, April N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045956/
https://www.ncbi.nlm.nih.gov/pubmed/35493124
http://dx.doi.org/10.1093/ofid/ofac172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045956/
https://www.ncbi.nlm.nih.gov/pubmed/35493124
http://dx.doi.org/10.1093/ofid/ofac172

Ejemplares similares